



Neuro Kinetics Announces Closing of \$2 Million Convertible Note Offering

PITTSBURGH, PA. January 18, 2017 — Neuro Kinetics, Inc. (NKI) announced today that its \$2 million Convertible Promissory Note (the "Note") offering was fully subscribed and closed as of December 7, 2016. The proceeds from this offering are being used to continue NKI's commercialization and expansion of its platform I-Portal® technology, with a particularly focus on both the final stages of clearing its new I-PAS™ (I-Portal Portable Assessment System) and building on the company's recent clinical trial successes with its emerging concussion-related applications.

I-PAS is already being used in a number of research clinical trials, primarily aimed at evaluating the device's clinical merit in relation to concussions or mild traumatic brain injuries. The company's ongoing development efforts are centered on gaining U.S. FDA clearances for a concussion indication.

"Closing on this important round of fundraising is an encouraging vote of confidence in NKI's strategic decision to pursue being the first FDA-cleared concussion indication. Investors include both existing and new private individuals, who recognize NKI's potential for future growth as a consequence of our pivotal role in neuro-functional assessments and concussion diagnostics," says Howison Schroeder, NKI's CEO.

Completing this Note brings the total risk capital raised by NKI to approximately \$6.6 million. Other funding sources for NKI's concussion-related R&D expenses have come from internal cash flow as well as research grants, and awards made by the U.S. Department of Defense and the Head Health Challenge II sponsors (the National Football League, Under Armour, Inc., and General Electric Company).

The clinical utility of I-Portal technology as a vestibular and neurotologic measurement tool in a concussion trial was highlighted in a news release (<http://tinyurl.com/NKI-on-PLOS-One>) that noted a recent study published in PLOS ONE. This and other studies conducted using I-Portal technology to date have separated concussed patients from a control group with exceptional sensitivity and specificity. Building on the aforementioned study's successful conclusions, NKI is developing in its I-PAS a screening tool, the Concussion Score™. The goal will be to secure clearances for use where quick *return-to-play* decisions need to be made, such as on sports fields, battlefields, emergency rooms and healthcare provider offices.

Beyond FDA-related efforts, a portion of the Note's proceeds will be applied to other working capital and general business purposes.

NKI is a privately held company. Details of the Notes' rates and terms are not disclosed. Neuro Kinetics acted as its own placement agent for the offering.



This news release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which, or to any person to whom, such offer, solicitation or sale is unlawful. The shares of common stock and warrants may only be offered by means of a prospectus.

About Neuro Kinetics, Inc.

The Science to See™

Neuro Kinetics, Inc. (NKI) is the leader in clinical eye-tracking and non-invasive neuro-otologic diagnostic testing. The eye is the portal to the brain and research has shown the detection of abnormal eye responses are used to diagnose more than 200 diseases and medical conditions.

With over 140 I-Portal installations, NKI's FDA cleared I-Portal® devices are sold to audiologists, ENT's, neurotologists, neuro-ophthalmologists and neurologists around the globe. The company's cleared patented diagnostic platforms include the I-Portal® NOTC (Neuro-Otologic Test Center), I-Portal® VNG (Video Nystagmography) and I-Portal® VOG (Video Oculography), along with related accessories, software, training and support services.

To learn more about NKI, please visit www.neuro-kinetics.com.

CONTACT:

J. Howison Schroeder
Neuro Kinetics, Inc.
412-963-6649
hschroeder@neuro-kinetics.com

Michael Saporito
Neuro Kinetics, Inc.
412-963-6649
msaporito@neuro-kinetics.com

END